Managing DIabetes Remission After Combined Therapy in EarLy Stage of DiabetEs

PHASE3CompletedINTERVENTIONAL

Enrollment

108

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

August 31, 2024

Study Completion Date

December 31, 2024

Conditions

Newly Diagnosed Type 2 Diabetes

Interventions

DRUG

Metformin-Sitagliptin-Empaglifozin-Pioglitazone

1000 mg metformin (extended release) b.i.d., pioglitazone 15 mg b.i.d., sitagliptin 100 mg q.d., empaglifozin 10 mg q.d..

DRUG

Standard of care

Usual medical care to treat diabetes.

Trial Locations (1)

Azienda Ospedaliero Universitaria di Parma, Parma

All Listed Sponsors

lead

Azienda Ospedaliero-Universitaria di Parma

OTHER

NCT04271189 - Managing DIabetes Remission After Combined Therapy in EarLy Stage of DiabetEs | Biotech Hunter | Biotech Hunter